Insufficient β-lactam concentrations in the early phase of severe sepsis and septic shock.
Taccone FS, Laterre PF, Dugernier T, Spapen H, Delattre I, Wittebole X, De Backer D, Layeux B, Wallemacq P, Vincent JL, Jacobs F. · 2010
Read Insufficient β-lactam concentrations in the early phase of severe sepsis and septic shock. by Taccone FS, Laterre PF, Dugernier T, Spapen H, Delattre I, Wittebole X, De Backer D, Layeux B, Wallemacq P, Vincent JL, Jacobs F. (2010) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc2945087.txt.
Introduction
Taccone and colleagues ran a 2010 study across four Belgian intensive care units. They checked whether standard first doses of common antibiotics reach strong enough blood levels in the sickest sepsis patients. Severe illness reshapes how drugs spread and clear from the body.
Eighty patients received one of four beta-lactam antibiotics, with blood sampled over the hours after the first dose. For each drug, levels stayed above a demanding target for only part of the dosing gap, ranging from about a third to just over half the interval. The results argue that first doses in severe sepsis often fall short.
Catalog record
| CREATOR | Taccone FS, Laterre PF, Dugernier T, Spapen H, Delattre I, Wittebole X, De Backer D, Layeux B, Wallemacq P, Vincent JL, Jacobs F. |
|---|---|
| YEAR | 2010 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 46 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Insufficient β-lactam concentrations in the early phase of severe sepsis and septic shock By Fabio Silvio Taccone, Pierre-François Laterre, Thierry Dugernier, Herbert Spapen, Isabelle Delattre, Xavier Wittebole, Daniel De Backer, Brice Layeux, Pierre Wallemacq, Jean-Louis Vincent, Frédérique Jacobs Published in: Critical Care DOI: 10.1186/cc9091 ABSTRACT Abstract Introduction Altered pharmacokinetics (PK) in critically ill patients can result in insufficient serum β-lactam concentrations when standard dosages are administered. Previous studies on β-lactam PK have generally excluded the most severely ill patients, or were conducted during the steady-state period of treatment. The aim of our study was to determine whether the first dose of piperacillin-tazobactam, ceftazidime, cefepime, and meropenem would result in adequate serum drug concentrations in patients with severe sepsis and septic shock. Methods Open, prospective, multicenter study in four Belgian intensive care units. All consecutive patients with a diagnosis of severe sepsis or septic shock, in whom treatment with the study drugs was indicated, were included. Serum concentrations of the antibiotics were determined by high-pressure liquid chromatography (HPLC) before and 1, 1.5, 4.5 and 6 or 8 hours after administration. Results 80 patients were treated with piperacillin-tazobactam (n = 27), ceftazidime (n = 18), cefepime (n = 19) or meropenem (n = 16). Serum concentrations remained above 4 times the minimal inhibitory concentration (T > 4 × MIC), corresponding to the clinical breakpoint for Pseudomonas aeruginosa defined by the European Committee on Antimicrobial Susceptibility Testing (EUCAST), for 57% of the dosage interval for meropenem (target MIC = 8 μg/mL), 45% for ceftazidime (MIC = 32 μg/mL), 34% for cefepime (MIC = 32 μg/mL), and 33% for piperacillin-tazobactam (MIC = 64 μg/mL). The number of patients who attained the target PK profile was 12/16 for meropenem (75%), 5/18 for ceftazidime (28%), 3/19 (16%) for cefepime, and 12/27 (44%) for piperacillin-tazobactam. Conclusions Serum concentrations of the antibiotic after the first dose were acceptable only for meropenem. Standard dosage regimens for piperacillin-tazobactam, ceftazidime and cefepime may, therefore, be insufficient to empirically cover less susceptible pathogens in the early phase of severe sepsis and septic shock. INTRODUCTION Severe sepsis and septic shock remain a major cause of morbidity and mortality in medical and surgical ICUs [1]. Although early and appropriate antibacterial therapy is considered a priority in the management of patients with sepsis [2,3], there is evidence that optimizing antibiotic dosage regimens to achieve therapeutic concentrations in the blood and at the site of infection is equally important [4]. Antibiotherapy in critically ill septic patients usually consists of a broad-spectrum β-lactam combined with a glycopeptide and/or an aminoglycoside [5]. These drugs cover a large variety of pathogens and can be empirically used for Gram-negative bacterial infections, including those caused by Pseudomonas aeruginosa. The activity of β-lactams is predominantly time-dependent and requires serum and tissue antibiotic concentrations above the minimal inhibitory concentration (MIC) of the pathogen to achieve adequate bacterial killing [6]. This effect is independent of peak levels and there is no significant post-antibiotic effect, except for carbapenems. Clinical data suggest that maximum killing of bacteria occurs when serum concentrations are maintained above the MIC of the causative pathogens for extended periods [7,8]; this may be especially appropriate in patients with compromised host-defences, including critically ill patients [9,10]. However, in conventional bolus dosing regimens, serum β-lactam concentrations may fall to low levels between doses [11,12], with potentially negative effects on clinical response and emergence of resistances. Antibiotic dosage regimens used in ICU patients are often based on pharmacokinetic (PK) data that were obtained in healthy volunteers or less severely ill patients. Moreover, they rarely take into account the dynamic changes of the septic process that can reduce the efficacy of anti-infective treatments and consequently affect patient outcomes [6]. During severe sepsis and septic shock, increased volume of distribution (Vd) and cardiac output can reduce serum drug concentrations, whereas decreased protein binding and end-organ dysfunction induce higher antibiotic levels [13]. Optimizing antibiotic dosage strategy should involve PK parameters, but therapeutic drug monitoring is necessary in septic patients because large inter-individual PK variations make it difficult to predict antibiotic levels [14]. As previous PK studies on β-lactams in ICU patients have excluded the most severely ill patients or were conducted in the steady-state period of treatment [15-17], the main objective of this study was to determine whether the currently recommended first dose of four broad-spectrum β-lactams (piperacillin-tazobactam, ceftazidime, cefepime, and meropenem) provide adequate plasma concentrations in critically ill septic patients in the ICU. We also tried to determine whether clinical or hemodynamic parameters could affect the PK profile of these drugs during such severe infections. MATERIALS AND METHODS Study design, patients, antibiotic treatment and data collection This was a prospective, multicenter, observational study performed in four Departments of Intensive Care in Belgium (at the St-Luc Hospital, Erasme Hospital, and UZ-VUB in Brussels and St Pierre Hospital in Ottignies). The study protocol was approved by the university ethics committees of the different hospitals. Before enrolment, written consent was obtained from the patient or their nearest relative. All patients admitted to one of the four ICUs between January 2005 and July 2006 were considered for inclusion. Inclusion criteria were a diagnosis of severe sepsis or septic shock [18], either at admission or during the ICU stay, and treatment with a broad-spectrum β-lactam antibiotic (ceftazidime, cefepime, piperacillin-tazobactam, or meropenem). Patients meeting one of the following criteria were excluded: age less than 18 years or more than 85 years; pregnancy or lactation; previous administration of any of the investigated antibiotics; chronic renal failure requiring dialysis; or allergy to any of the investigated antibiotics. The study period was limited to the first 24 hours of antibiotherapy. Administration of the four β-lactams was made according to local guidelines. These drugs are generally used in the participating centers to treat hospital- or ICU-acquired infections or in the case of community-acquired infection when a more-resistant pathogen may be involved (recent hospitalization or antibiotic therapy, previous colonization by more resistant strain). Piperacillin-tazobactam was preferred as first-line therapy in cases of proven or suspected intra-abdominal infections. Ceftazidime and cefepime was used as first-line therapy in other cases. Meropenem was used as second-line therapy (i.e. failure of piperacillin-tazobactam or cephalosporins) or in case of suspected or previous colonization by extended spectrum beta-lactamase Gram-negative bacteria. In all study patients, demographics, pre-existing chronic diseases, admission diagnosis and biological data were collected in institutional databases. The severity of illness of each patient was characterized using the Acute Physiology and Chronic Health Evaluation (APACHE) II [19] and sequential organ failure assessment (SOFA) [20] scores determined on the first day of antibiotic treatment. Creatinine clearance (CrCl) was calculated using a standard formula [21]. Treatment of patients with catecholamines, mechanical ventilation, hemofiltration or hemodialysis was recorded, as was length of ICU and hospital stay, overall mortality, and cause of death. Hemodynamic data were collected at baseline, and 8 and 24 hours after the start of the protocol. Analytic method for β-lactams All the patients included in the study received a first dose of 2 g ceftazidime or cefepime, 4 g/0.5 g piperacillin-tazobactam, or 1 g meropenem. The usual daily doses of these antibiotics and dose adjustments for renal function are presented in Additional file 1. All the patients also received amikacin and the two